
ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
-- Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment -- TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology …